Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer
Not Applicable
Active, not recruiting
- Conditions
- Stage IIIA Cervical Cancer FIGO 2018Stage IB2 Cervical Cancer FIGO 2018Stage IIA Cervical Cancer FIGO 2018Cervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedStage II Cervical Cancer FIGO 2018Stage IIB Cervical Cancer FIGO 2018Cervical AdenocarcinomaStage IB3 Cervical Cancer FIGO 2018Stage IIA2 Cervical Cancer FIGO 2018
- Interventions
- Other: Media InterventionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationOther: Survey AdministrationProcedure: Yoga
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04622670
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1
Recruiting
- Conditions
- Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Thoracic Esophagus AdenocarcinomaCervical Esophagus AdenocarcinomaGastroesophageal Junction AdenocarcinomaPathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Interventions
- Drug: CapecitabineDrug: CarboplatinDrug: DocetaxelDrug: FluorouracilOther: Hafnium Oxide-containing Nanoparticles NBTXR3Radiation: Intensity-Modulated Radiation TherapyDrug: LeucovorinDrug: OxaliplatinDrug: Paclitaxel
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04615013
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
Phase 1
Active, not recruiting
- Conditions
- Metastatic Colon AdenocarcinomaStage IIIA Colon Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Recurrent Colorectal CarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT04616183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Project Self in Improving Cervical Cancer Screening Rates in Hispanic and African American Women
Not Applicable
Active, not recruiting
- Conditions
- Healthy Subject
- Interventions
- Other: Educational InterventionProcedure: HPV Self-CollectionOther: Questionnaire Administration
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04614155
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Self-monitoring Focus Groups With Vibrant Lives Pasadena Participants
Recruiting
- Conditions
- Obesity-Related Malignant Neoplasm
- Interventions
- Behavioral: DiscussionOther: InterviewOther: Survey Administration
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT04611087
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
Active, not recruiting
- Conditions
- Malignant Head and Neck NeoplasmMalignant Solid NeoplasmEsophageal CarcinomaLung Carcinoma
- Interventions
- Procedure: Quality-of-Life AssessmentOther: Best PracticeOther: Questionnaire AdministrationProcedure: Yoga
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 600
- Registration Number
- NCT04607590
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
Recruiting
- Conditions
- FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Interventions
- Procedure: Bilateral Salpingectomy with OophorectomyProcedure: Biospecimen CollectionProcedure: HysterectomyOther: Laboratory Biomarker AnalysisProcedure: Lymph Node MappingProcedure: Sentinel Lymph Node Biopsy
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 500
- Registration Number
- NCT04604613
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
Phase 4
Recruiting
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Drug: Nicotine ReplacementDrug: Bupropion Hydrochloride Controlled-releaseOther: Questionnaire AdministrationDrug: VareniclineOther: Tobacco Cessation Counseling
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2010
- Registration Number
- NCT04604509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
Recruiting
- Conditions
- Bronchiolitis Obliterans
- Interventions
- Procedure: Biospecimen CollectionOther: Medical Chart Review
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04604522
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
Phase 1
Recruiting
- Conditions
- Metastatic Colon AdenocarcinomaStage III Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Metastatic Colorectal CarcinomaStage III Colon Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8
- Interventions
- Drug: CXCR1/2 Inhibitor SX-682Biological: Nivolumab
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT04599140
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath